Loading
A phase 2 trial of Enzalutamide and Mifepristone in Breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06099769 by Memorial Sloan Kettering Cancer Center, with 201 participants planned, started 2023-10-18 and due to reach its primary completion in 2027-10. Interventions recorded: Enzalutamide, Mifepristone, TPC. Conditions recorded: Metastatic Breast Cancer.
Linked to the drug Mifepristone because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mifepristone, Breast cancer (all types) and the tag pipeline.
Shares Mifepristone, Breast cancer (all types) and the tag pipeline.
Shares Enzalutamide and the tag pipeline.
Shares Enzalutamide and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/